tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Depth

tanzania times : Latest News and In-depth Analysis
HomeDepth
Depth

Mar 18, 2025

MicroAlgo Inc. Develops Multi-Simulator Collaborative Algorithm Based on Subgraph Isomorphism to Enhance Quantum Computer Performance Using Distributed Computing Advantages

SHENZHEN,China,March 17,2025-- MicroAlgo Inc. (NASDAQ: MLGO),(the "Company"or "MicroAlgo"),today announced the introduction of an innovative solution: a multi-simulator collaborati

All News

Nel ASA: Signs collaboration agreement and conducts private placement with SAMSUNG E&A

OSLO,Norway,March 12,2025-- Nel ASA (Nel,OSE:NEL) has signed an EPC collaboration agreement that allows SAMSUNG E&A to offer its customers complete hydrogen plants of its own design using Nel\'s e

Mar 12, 2025

Depth

TraceLink Selected as a CIOReview Top Supply Chain Solution Provider of 2025

BOSTON,March 11,2025-- TraceLink,the largest end-to-end digital network platform for intelligent orchestration of the supply chain,has been recognized by CIOReview as a Top Supply Chain Solution Prov

Mar 12, 2025

Depth

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

SHANGHAI and SEOUL,South Korea,March 11,2025-- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company",stock code: 2268.HK),a leading global CRDMO (Contract Research,Development,and Manu

Mar 12, 2025

Cloud4C recognized as a Microsoft Security Excellence Awards finalist for Endpoint Management Trailblazer Award

SINGAPORE,March 12,2025-- Cloud4C today announced it is an Endpoint Management Trailblazer award finalist in the Microsoft Security Excellence Awards. The company was honored among a global field of i

Mar 12, 2025

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

ASC47,an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity,demonstrated a half-life of up to 26 days and 40 days,respectively,in Phase Ib single subcutaneous i

Mar 12, 2025

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG,March 12,2025-- AIM Vaccine Co.,Ltd. (06660.HK),a leading PRC vaccine company,published an announcement on March 12

Mar 12, 2025

1 ... 32 33 34 35 36 37 38 ... 99